MedTrace Logo

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

NCT06118866 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2025-06-04

No results posted yet for this study

Summary

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

Conditions

Interventions

DRUG

placebo-Q2W

placebo, 0mg，SC，Q2W，12 cycles

DRUG

HMI-115-120mg-Q4W

HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

DRUG

HMI-115-240mg-Q4W

HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

DRUG

HMI-115, 240mg-Q2W

HMI-115, 240mg，SC，Q2W，12 cycles

Sponsors & Collaborators

  • Hope Medicine (Nanjing) Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-11
Primary Completion
2024-08-26
Completion
2024-11-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118866 on ClinicalTrials.gov